Here, nanobody-based CD38-specific hcAbs are able to induce antibody-dependent cellular cytotoxicity in tumor cancer cell lines and inhibit tumor growth in a mouse xenograft model, warranting further clinical development as therapeutics for multiple myeloma and other hematological malignancies (Schriewer et al. 2020). The gene discussed is CD38; the disease is plasma cell myeloma.